Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2009) 20 P459

ECE2009 Poster Presentations Obesity and Metabolism (70 abstracts)

Influence of metformin on selected lipids and apolipoproteins concentrations in young women with metabolic syndrome

Justyna Kuliczkowska-Plaksej , Grazyna Bednarek-Tupikowska , Alicja Filus , Anna Trzmiel-Bira & Andrzej Milewicz


Department of Endocrinology, Diabetology and Isotope Therapy, Medical University Wroclaw, Wroclaw, Poland.


Introduction: Metabolic syndrome (MS) is connected to atherogenic dyslipidemia. Data concerning influence of metformin (MET) therapy on lipid profile in nondiabetic women with MS remains unclear.

Aim: To asses the influence of MET on selected lipid, apolipoproteins AI, B concentrations and atherogenic indexes values in young women with MS.

Materials and methods: The study population: 30 women with MS aged 25–45 years before (M1) and after (M2) MET therapy (1700 mg per day for 4 months). Control group (C): 15 nonobese women. Total cholesterol (TC), LDL-C, HDL-C, HDL2-C, triglycerides (TG), apolipoprotein AI (ApoAI) and B (ApoB), fasting glucose and insulin concentrations were estimated. Atherogenic index of plasma (AIP), Castelli index, LDL-C/HDL-C, TC/HDL-C, apoB/apoAI, HOMA, FIRI, QUICKI indexes were estimated. All parameters were evaluated before and after MET.

Results: In M1 group we found higher TC, LDL-C, TG, ApoB and lower HDL-C, HDL2-C, ApoAI concentrations than in nonobese women. HDL-C concentration increased and TG decreased significantly after therapy. Atherogenic indexes values were higher in M1 than in C, significantly decreased after therapy, except for ApoB/AI, and were still higher than in C. Fasting glucose and insulin concentrations, HOMA, FIRI were the highest and QUICKI was the lowest in M1, did not change after MET.

Coclusions: MET positively modifies lipid profile and atherogenic indexes values in women with MS.

Article tools

My recent searches

No recent searches.